ArticleBMC anesthesiology2026
Prognostic impact of sepsis-induced coagulopathy on mortality and clinical outcomes in ICU patients.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the prognostic impact of sepsis-induced coagulopathy (SIC) on mortality and clinical outcomes in patients with sepsis admitted to the intensive care unit (ICU). MATERIALS AND
methodsThis retrospective cohort study included 1,305 adult patients with sepsis admitted to a tertiary pulmonary ICU between January 2016 and May 2025. SIC was defined using the International Society on Thrombosis and Haemostasis (ISTH) criteria, based on platelet (PLT) count, prothrombin time/international normalized ratio (PT/INR), and total Sequential Organ Failure Assessment (SOFA) score components. The primary outcome was in-hospital mortality, and secondary outcomes included vasopressor requirement, escalation to second-line vasopressor therapy, invasive mechanical ventilation (IMV), and continuous renal replacement therapy (CRRT). Multivariable logistic regression and receiver operating characteristic (ROC) analyses were conducted to assess the prognostic value of SIC.
resultsThe prevalence of SIC was 19.2%. Patients with SIC had significantly higher in-hospital mortality than those without SIC (79.3% vs. 60.6%, p < 0.001). Vasopressor use and escalation to second-line vasopressor therapy were more frequent in the SIC-positive group (98.0% vs. 92.5%, p = 0.001; 45.8% vs. 31.3%, p < 0.001, respectively). In multivariable analyses, both SIC positivity (OR: 2.172, 95% CI: 1.528-3.087, p < 0.001) and the SIC score (OR: 1.324, 95% CI: 1.175-1.492, p < 0.001) were independently associated with mortality. ROC analysis showed that the SIC score had moderate discriminative performance for predicting mortality (AUC: 0.619, 95% CI: 0.588-0.649, p < 0.001), with an SIC score ≥ 4 identified as the clinically interpreted threshold.
conclusionSIC was independently associated with higher in-hospital mortality and greater need for vasopressor support in critically ill patients with sepsis. These findings suggest that SIC may provide complementary prognostic information when interpreted alongside established severity assessment tools; however, prospective studies are needed to clarify its clinical relevance and potential role in patient management.
Indexed as
Identifiers
42471569What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.